Luciano Rossetti, MD, head of Global Scientific Strategy, Merck Research Laboratories, talks about the discovery of PD-L1 and how the finding has evolved into potential treatments for bladder cancer patients, specifically avelumab.
Luciano Rossetti, MD, head of Global Scientific Strategy, Merck Research Laboratories, talks about the discovery of PD-L1 and how the finding has evolved into potential treatments for bladder cancer patients, specifically avelumab.
Avelumab targets PD-L1 and blocks its interaction with PD-1 and ultimately deters the tumor in paralyzing a patient’s immune response. Rossetti says that anti-PD-L1 therapies are being looked at as monotherapies, first- and second-line therapies, as well as being used in combination with other therapies.
Behind the FDA Approval of Liso-cel for Relapsed/Refractory CLL/SLL
March 15th 2024In an interview with Targeted Oncology, Tanya Siddiqi, MD, discussed the rationale behind the TRANSCEND CLL 004 study supporting the FDA approval of lisocabtagene maraleucel in chronic lymphocytic leukemia or small lymphocytic lymphoma.
Read More